查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1771449

全球动物生物製品市场：依产品类型、疾病类型、应用、通路、地区、机会及预测，2018-2032

Global Veterinary Biologics Market Assessment, By Product, By Disease Type, By Application, By Distribution Channel, By Region, Opportunities and Forecast, 2018-2032F
出版日期: | 出版商: Markets & Data | 英文 232 Pages | 商品交期: 3-5个工作天内

价格

全球动物生物製品市场预计将从2024年的171.3亿美元成长到2032年的271.4亿美元，在2025-2032年的预测期内，年复合成长率为5.92%。由于动物生物製品作为生物製品，可为动物提供疾病预防、治疗和诊断功能，预计全球动物生物製品市场的需求将持续成长。这些产品包括疫苗、菌苗和诊断试剂盒，其成分均来自活体生物体。由于这些产品是保护动物健康、阻止疾病传播的重要工具，因此其需求也持续成长。

全球动物生物製品市场透过分销疫苗、抗血清和血液製品等用于保护动物免受疾病侵害的生物製品，在动物保健领域发挥着非常重要的作用。由于全球牲畜和宠物数量的增加，以及人们对动物健康认知的提升和人畜共患疾病病例的增加，该市场持续大幅扩张。生物开发领域的技术进步带来了更先进的生物製品，推动了市场的持续成长。政府的动物健康计画、主要产业参与者不断增加的投资以及人们对食品安全和公共卫生日益成长的关注，是推动兽用生物製品需求的主要因素。由于宠物主人数量的增加，尤其是在已开发国家，伴侣动物生物製品的消费量也不断增加。市场依产品类别、动物类别、应用领域和区域细分进行分析，其中疫苗占比最大，因为它们是预防疾病的重要措施。北美和欧洲是市场发展最快的地区，因为这些地区拥有发达的医疗保健体系、完善的法规以及大量的宠物主人。由于畜牧业的扩张以及发展中国家意识的提高和经济发展，亚太市场将呈现最高的成长率。

同时，在动物生物製品的开发方面，各公司建立合作伙伴关係，以改善动物健康。例如，2024年8月，Akston Biosciences Corporation与Purdue University宣布达成策略合作，重点是共同开发抗cPD-L1单株抗体（mAb）免疫疗法，用于治疗犬隻癌症。

目录

第1章 专案范围与定义

第2章 研究方法

第3章 美国关税的影响

第4章 执行摘要

第5章 2018-2032年全球动物生物製品市场展望

  • 市场规模分析与预测
    • 依价值
  • 市场占有率分析与预测
    • 依产品
      • 疫苗
      • 诊断试剂盒
      • 免疫调节剂
      • 抗血清和抗体
      • 其他
    • 依疾病类型
      • 蓝舌病
      • 口蹄疫
      • 布鲁氏鼻炎、结核病
      • 其他
    • 依应用
      • 家畜
      • 伴侣动物
    • 依通路
      • 兽医院
      • 兽医诊所
      • 零售药局
    • 依地区
      • 北美
      • 欧洲
      • 亚太地区
      • 南美
      • 中东和非洲
    • 市场占有率分析公司（前五名及其他 - 依价值，2024年）
  • 2024年市场地图分析
    • 依产品
    • 依疾病类型
    • 依应用
    • 依通路
    • 依地区

第6章 2018-2032年北美动物生物製品市场展望

  • 市场规模分析与预测
    • 依价值
  • 市场占有率分析与预测
    • 依产品
      • 疫苗
      • 诊断试剂盒
      • 免疫调节剂
      • 抗血清和抗体
      • 其他
    • 依疾病类型
      • 蓝舌病
      • 口蹄疫
      • 布鲁氏菌病与结核病
      • 其他
    • 依用途
      • 牲畜
      • 伴侣动物
    • 依通路
      • 兽医院
      • 兽医诊所
      • 零售药局
    • 依国家/地区市场占有率
      • 美国
      • 加拿大
      • 墨西哥
  • 依国家/地区市场评估
    • 美国2018-2032年动物生物製品市场展望
      • 市场规模分析与预测
      • 市场占有率分析与预测
    • 加拿大
    • 墨西哥

第7章 2018-2032年欧洲动物生物製品市场展望

  • 德国
  • 法国
  • 义大利
  • 英国
  • 俄罗斯
  • 荷兰
  • 西班牙
  • 土耳其
  • 波兰

第8章 2018-2032年亚太地区动物生物製品市场展望

  • 印度
  • 中国
  • 日本
  • 澳洲
  • 越南
  • 南非韩国
  • 印尼
  • 菲律宾

第9章 2018-2032年南美洲动物生物製品市场展望

  • 巴西
  • 阿根廷

第10章 2018-2032年中东及非洲动物生物製品市场展望

  • 沙乌地阿拉伯
  • 阿拉伯联合大公国
  • 南非

第11章 需求与供给分析

第12章 价值链分析

第13章 波特五力分析

第14章 PESTLE分析

第15章 临床试验

第16章 市场动态

  • 市场驱动因素
  • 市场挑战

第17章 市场趋势与发展

第18章 监理格局

第19章 个案研究

第20章 竞争格局

  • 五大市场领导者竞赛矩阵
  • 五大公司SWOT分析
  • 市场十大主要参与者情势
    • Bayer AG
    • Eli Lilly &Company
    • Evonik Industries AG
    • Zoetis Inc.
    • Merck & Co., Inc.
    • Boehringer Ingelheim International GmbH
    • Elanco Animal Health Incorporated
    • IDEXX Laboratories Inc.
    • Virbac SA
    • Phibro Animal Health Corporation

第21章 策略建议

第22章 关于调查公司/免责声明

Product Code: MX13642

Global veterinary biologics market is projected to witness a CAGR of 5.92% during the forecast period 2025-2032, growing from USD 17.13 billion in 2024 to USD 27.14 billion in 2032. The global veterinary biologics market demand is projected to rise as veterinary biologics serve as biological products that provide disease prevention or treatment and diagnostic capabilities for animals. The products, which consist of vaccines, bacterins, and diagnostic test kits, derive their components from living organisms. Also, the need for these products is rising consistently as these products function as essential tools that protect animal health while stopping diseases from spreading.

The global veterinary biologics market plays a crucial role in animal healthcare by distributing biological products, including include vaccines, antisera, and blood products used to protect animals from diseases. The market continues to expand significantly because of growing animal health knowledge and increasing cases of zoonotic diseases alongside expanding worldwide populations of livestock and pets. Technological progress in the field of biological development has produced enhanced biologics that drive the market's ongoing growth. Government programs for animal health and increasing investments from important industry players, and rising focus on food safety and public health serve as major factors driving the demand for veterinary biological. The increasing number of pets being adopted, particularly in developed countries, has led to greater consumption of biologics designed for companion animals. The market divides its analysis into product categories, animal categories, application segments, and regional divisions, with vaccines maintaining the largest portion since they serve as essential preventive measures against diseases. The market leaders include North America and Europe since these regions possess developed healthcare systems and supportive regulations, together with high numbers of pet owners. The market in the Asia-Pacific will experience the highest growth rate due to expanding livestock operations and increasing awareness and economic progress in developing nations.

At the same time, for the development of veterinary biologics, companies are forming partnerships to improve animal health. For instance, in August 2024, Akston Biosciences Corporation and Purdue University announced a strategic partnership to focus on co-developing an anti-cPD-L1 monoclonal antibody (mAb) immunotherapy to treat cancer in dogs.

Rising Prevalence of Zoonotic Diseases Increased Market Demand

The rising prevalence of zoonotic disease caused a major increase in the demand for veterinary biologics. The increasing prevalence of diseases such as COVID-19, together with avian influenza and rabies, requires immediate control measures to prevent their transmission from animals to humans. Public health protection through disease prevention in animals has become clear to both government agencies and healthcare providers, as well as livestock owners. Veterinary biologics experience significant market interest because vaccines, together with diagnostics and therapeutics, function as essential tools for outbreak response and current infection control. The expanding implementation of biosecurity measures and vaccination approaches generates growing requirements for veterinary biologics. The rising number of pet owners and livestock farmers has generated increased requirements for dependable biological products that support animal health and productivity. The increasing threat from zoonotic diseases has caused major expansion in the veterinary biologics market because these products serve essential functions for disease prevention worldwide.

For instance, in March 2024, a Spanish National Research Council announced collaboration with Zendal group launched Neoleish, the world's first DNA vaccine against canine leishmaniasis a serious zoonosis that can also be transmitted from animals to humans.

Advancements in Biotechnology Enhance Veterinary Biologics Market Demand

Developments in biotechnology alongside genetic engineering enable significant advancements in veterinary biologics development. The recent progress in recombinant vaccines and monoclonal antibodies alongside DNA-based immunizations improves therapeutic outcomes and lowers potential side effects. The contemporary biologics function by specifically identifying pathogens to generate enhanced immune responses that maintain protection for longer periods in livestock and pet animals. Scientists utilize genetic engineering methods to develop multivalent vaccines that merge numerous disease defenses within a single shot to reduce vaccination complexity and minimize the number of doses needed. Animal handling during repeated procedures remains difficult and causes stress to both livestock and farm workers in large-scale farming operations. Biologics become more appealing to veterinary practitioners and farmers in emerging economies through these innovations because they provide cost-effective and simple-to-use solutions. Modern biologics enhance disease resistance while minimizing multiple intervention needs to produce better animal health alongside increased productivity and sustainable farming methods. Global veterinary biologics will benefit from innovative research in gene editing and synthetic biology, which will generate advanced solutions for the future.

Additionally, to develop innovative vaccines, biotech firms received approval from the drug department. For instance, in January 2023, Dalan Animal Health, Inc., a biotech firm focused on insect health, announced that the U.S. Department of Agriculture (USDA) had granted a conditional license for the immunization of honeybees against American Foulbrood disease caused by Paenibacillus larvae.

Vaccines Hold the Largest Global Veterinary Biologics Market Share

The veterinary biologics market consists of vaccines because they provide essential disease prevention and control for animals. The administration cost remains low while the effectiveness of these vaccines stands high to protect animals from diseases, including rabies, foot-and-mouth disease, and avian influenza. The rising knowledge among farmers, together with pet owners, regarding animal health maintenance and disease prevention, creates increasing market demand for veterinary vaccines. Modern vaccine technology developments through recombinant and DNA-based vaccines have enhanced both their safety and effectiveness, which drives their growing market acceptance. The vaccine segment experiences market growth because of government programs that fight zoonotic diseases, along with regulatory approval processes. The veterinary biologics market will maintain its top position through vaccines because livestock production worldwide grows steadily and requires efficient immunization solutions. The protective function of vaccines safeguards animal health and preserves food supply chains which further helps agricultural businesses avoid monetary losses, driving the global market demand.

For instance, in September 2024, Merck & Co., Inc., announced that it would expand its new USDA-approved NOBIVAC NXT vaccine platform to add a best-in-class solution to protect cats against feline leukemia virus, one of the most common infectious diseases in cats. The company expects the vaccine will be available at veterinary clinics and hospitals nationwide this fall.

North America Dominates the Veterinary Biologics Market Size

North America leads the veterinary biologics market through its superior healthcare system and extensive knowledge of animal health, and large-scale R&D funding. Regional regulations impose rigorous standards that ensure the safety and effectiveness of biologic products, thus making consumers feel secure. Major veterinary companies in the U.S. and Canada create new vaccines to fight animal diseases, including rabies, avian influenza, and foot-and-mouth disease. The expanding pet ownership trends and increasing veterinary service requirements support ongoing market development. The veterinary biologics market expands through government-backed animal health programs, together with disease control initiatives. The distribution networks in North America, together with established veterinary clinics, allow biologic products to reach a broad customer base. North America leads the global veterinary biologics market because of its technological progress, together with extensive pet ownership and government initiatives for animal health.

For instance, in July 2023, Invetx, Inc. announced the completed development of their species-specific, half-life extension technology application for dogs and cats, which can enhance the extended duration of activity for the company's veterinary monoclonal antibodies. This novel technology allows the company to optimize evidence-based antibody drug treatment options for a precious animal's chronic, serious diseases. Invetx has been issued four patents in the U.S. relating to their half-life extension technology, and has multiple patents pending in the U.S., Europe, and other jurisdictions.

Impact of U.S. Tariffs on Global Veterinary Biologics Market

The veterinary biologics market experiences substantial effects from U.S. tariffs through changes to import expenses, pricing structures, and market competitiveness. When foreign biologics face elevated tariffs on their imported vaccines and diagnostics, and other biological products become more expensive which may drive up prices for veterinary practices and their customers. Domestic manufacturers receive encouragement to increase their production capabilities through this situation, yet restricted domestic capacity might reduce product diversity and innovation development. Tariffs create obstacles for international trade, which result in delayed availability of advanced biologics and supply chain disruptions. The implementation of tariffs by trading partners happens as a defensive reaction to these measures, thus generating additional market instability. The veterinary biologics market faces tariff-induced alterations in pricing levels and supply availability alongside changes to innovation patterns, which impact both animal health management and the broader agricultural industry. The protection of domestic industries versus affordable veterinary biologics access stands as a primary concern for all involved stakeholders.

Key Players Landscape and Outlook

Major players in the veterinary biologics market are a highly competitive scenario. These companies continually attempt to expand the market and improve their competitive position. They want to be seen as developed markets that want to introduce new products that meet people's needs through research and development. Key players in the veterinary biologics market pursue acquisitions and mergers as a strategy to expand their product portfolios. The veterinary biologics market will experience fast growth because several factors drive its expansion, including rising animal populations, growing animal protein demand and increasing awareness about animal health. The veterinary biologics market operates in a highly competitive environment because the main industry players strive to improve their market position.

In May 2023, Zoetis Inc. announced the approval of Librela (bedinvetmab injection) from the U.S. Food and Drug Administration (FDA) to control pain associated with osteoarthritis (OA) in dogs.

In October 2024, Elanco Animal Health Incorporated received a grant from the U.S. Food and Drug Administration (FDA) for Credelio Quattro to make the most expansive canine oral parasiticide available in the market because it protects against six types of parasites.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Impact of U.S. Tariffs

4. Executive Summary

5. Global Veterinary Biologics Market Outlook, 2018-2032F

  • 5.1. Market Size Analysis & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share Analysis & Forecast
    • 5.2.1. By Product
      • 5.2.1.1. Vaccines
      • 5.2.1.2. Diagnostic Kits
      • 5.2.1.3. Immunomodulators
      • 5.2.1.4. Antiserums and Antibodies
      • 5.2.1.5. Others
    • 5.2.2. By Disease Type
      • 5.2.2.1. Bluetongue
      • 5.2.2.2. Foot and Mouth Disease
      • 5.2.2.3. Brucellosis and Tuberculosis
      • 5.2.2.4. Others
    • 5.2.3. By Application
      • 5.2.3.1. Production Animal
      • 5.2.3.2. Companion Animal
    • 5.2.4. By Distribution Channel
      • 5.2.4.1. Veterinary Hospitals
      • 5.2.4.2. Veterinary Clinics
      • 5.2.4.3. Retail Pharmacies
    • 5.2.5. By Region
      • 5.2.5.1. North America
      • 5.2.5.2. Europe
      • 5.2.5.3. Asia-Pacific
      • 5.2.5.4. South America
      • 5.2.5.5. Middle East and Africa
    • 5.2.6. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2024)
  • 5.3. Market Map Analysis, 2024
    • 5.3.1. By Product
    • 5.3.2. By Disease Type
    • 5.3.3. By Application
    • 5.3.4. By Distribution Channel
    • 5.3.5. By Region

6. North America Veterinary Biologics Market Outlook, 2018-2032F

  • 6.1. Market Size Analysis & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share Analysis & Forecast
    • 6.2.1. By Product
      • 6.2.1.1. Vaccines
      • 6.2.1.2. Diagnostic Kits
      • 6.2.1.3. Immunomodulators
      • 6.2.1.4. Antiserums and Antibodies
      • 6.2.1.5. Others
    • 6.2.2. By Disease Type
      • 6.2.2.1. Bluetongue
      • 6.2.2.2. Foot and Mouth Disease
      • 6.2.2.3. Brucellosis and Tuberculosis
      • 6.2.2.4. Others
    • 6.2.3. By Application
      • 6.2.3.1. Production Animal
      • 6.2.3.2. Companion Animal
    • 6.2.4. By Distribution Channel
      • 6.2.4.1. Veterinary Hospitals
      • 6.2.4.2. Veterinary Clinics
      • 6.2.4.3. Retail Pharmacies
    • 6.2.5. By Country Share
      • 6.2.5.1. United States
      • 6.2.5.2. Canada
      • 6.2.5.3. Mexico
  • 6.3. Country Market Assessment
    • 6.3.1. United States Veterinary Biologics Market Outlook, 2018-2032F*
      • 6.3.1.1. Market Size Analysis & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share Analysis & Forecast
        • 6.3.1.2.1. By Product
          • 6.3.1.2.1.1. Vaccines
          • 6.3.1.2.1.2. Diagnostic Kits
          • 6.3.1.2.1.3. Immunomodulators
          • 6.3.1.2.1.4. Antiserums and Antibodies
          • 6.3.1.2.1.5. Others
        • 6.3.1.2.2. By Disease Type
          • 6.3.1.2.2.1. Bluetongue
          • 6.3.1.2.2.2. Foot and Mouth Disease
          • 6.3.1.2.2.3. Brucellosis and Tuberculosis
          • 6.3.1.2.2.4. Others
        • 6.3.1.2.3. By Application
          • 6.3.1.2.3.1. Production Animal
          • 6.3.1.2.3.2. Companion Animal
        • 6.3.1.2.4. By Distribution Channel
          • 6.3.1.2.4.1. Veterinary Hospitals
          • 6.3.1.2.4.2. Veterinary Clinics
          • 6.3.1.2.4.3. Retail Pharmacies
    • 6.3.2. Canada
    • 6.3.3. Mexico

All segments will be provided for all regions and countries covered

7. Europe Veterinary Biologics Market Outlook, 2018-2032F

  • 7.1. Germany
  • 7.2. France
  • 7.3. Italy
  • 7.4. United Kingdom
  • 7.5. Russia
  • 7.6. Netherlands
  • 7.7. Spain
  • 7.8. Turkey
  • 7.9. Poland

8. Asia-Pacific Veterinary Biologics Market Outlook, 2018-2032F

  • 8.1. India
  • 8.2. China
  • 8.3. Japan
  • 8.4. Australia
  • 8.5. Vietnam
  • 8.6. South Korea
  • 8.7. Indonesia
  • 8.8. Philippines

9. South America Veterinary Biologics Market Outlook, 2018-2032F

  • 9.1. Brazil
  • 9.2. Argentina

10. Middle East and Africa Veterinary Biologics Market Outlook, 2018-2032F

  • 10.1. Saudi Arabia
  • 10.2. UAE
  • 10.3. South Africa

11. Demand Supply Analysis

12. Value Chain Analysis

13. Porter's Five Forces Analysis

14. PESTLE Analysis

15. Clinical Trials

16. Market Dynamics

  • 16.1. Market Drivers
  • 16.2. Market Challenges

17. Market Trends and Developments

18. Regulatory Landscape

19. Case Studies

20. Competitive Landscape

  • 20.1. Competition Matrix of Top 5 Market Leaders
  • 20.2. SWOT Analysis for Top 5 Players
  • 20.3. Key Players Landscape for Top 10 Market Players
    • 20.3.1. Bayer AG
      • 20.3.1.1. Company Details
      • 20.3.1.2. Key Management Personnel
      • 20.3.1.3. Products and Services
      • 20.3.1.4. Financials (As Reported)
      • 20.3.1.5. Key Market Focus and Geographical Presence
      • 20.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
    • 20.3.2. Eli Lilly & Company
    • 20.3.3. Evonik Industries AG
    • 20.3.4. Zoetis Inc.
    • 20.3.5. Merck & Co., Inc.
    • 20.3.6. Boehringer Ingelheim International GmbH
    • 20.3.7. Elanco Animal Health Incorporated
    • 20.3.8. IDEXX Laboratories Inc.
    • 20.3.9. Virbac S.A.
    • 20.3.10. Phibro Animal Health Corporation

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

21. Strategic Recommendations

22. About Us and Disclaimer

List of Tables

  • Table 1. Competition Matrix of Top 5 Market Leaders
  • Table 2. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 3. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Veterinary Biologics Market, By Value, In USD Billion, 2018-2032F
  • Figure 2. Global Veterinary Biologics Market Share (%), By Product, 2018-2032F
  • Figure 3. Global Veterinary Biologics Market Share (%), By Disease Type, 2018-2032F
  • Figure 4. Global Veterinary Biologics Market Share (%), By Application, 2018-2032F
  • Figure 5. Global Veterinary Biologics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 6. Global Veterinary Biologics Market Share (%), By Region, 2018-2032F
  • Figure 7. North America Veterinary Biologics Market, By Value, In USD Billion, 2018-2032F
  • Figure 8. North America Veterinary Biologics Market Share (%), By Product, 2018-2032F
  • Figure 9. North America Veterinary Biologics Market Share (%), By Disease Type, 2018-2032F
  • Figure 10. North America Veterinary Biologics Market Share (%), By Application, 2018-2032F
  • Figure 11. North America Veterinary Biologics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 12. North America Veterinary Biologics Market Share (%), By Country, 2018-2032F
  • Figure 13. United States Veterinary Biologics Market, By Value, In USD Billion, 2018-2032F
  • Figure 14. United States Veterinary Biologics Market Share (%), By Product, 2018-2032F
  • Figure 15. United States Veterinary Biologics Market Share (%), By Disease Type, 2018-2032F
  • Figure 16. United States Veterinary Biologics Market Share (%), By Application, 2018-2032F
  • Figure 17. United States Veterinary Biologics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 18. Canada Veterinary Biologics Market, By Value, In USD Billion, 2018-2032F
  • Figure 19. Canada Veterinary Biologics Market Share (%), By Product, 2018-2032F
  • Figure 20. Canada Veterinary Biologics Market Share (%), By Disease Type, 2018-2032F
  • Figure 21. Canada Veterinary Biologics Market Share (%), By Application, 2018-2032F
  • Figure 22. Canada Veterinary Biologics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 23. Mexico Veterinary Biologics Market, By Value, In USD Billion, 2018-2032F
  • Figure 24. Mexico Veterinary Biologics Market Share (%), By Product, 2018-2032F
  • Figure 25. Mexico Veterinary Biologics Market Share (%), By Disease Type, 2018-2032F
  • Figure 26. Mexico Veterinary Biologics Market Share (%), By Application, 2018-2032F
  • Figure 27. Mexico Veterinary Biologics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 28. Europe Veterinary Biologics Market, By Value, In USD Billion, 2018-2032F
  • Figure 29. Europe Veterinary Biologics Market Share (%), By Product, 2018-2032F
  • Figure 30. Europe Veterinary Biologics Market Share (%), By Disease Type, 2018-2032F
  • Figure 31. Europe Veterinary Biologics Market Share (%), By Application, 2018-2032F
  • Figure 32. Europe Veterinary Biologics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 33. Europe Veterinary Biologics Market Share (%), By Country, 2018-2032F
  • Figure 34. Germany Veterinary Biologics Market, By Value, In USD Billion, 2018-2032F
  • Figure 35. Germany Veterinary Biologics Market Share (%), By Product, 2018-2032F
  • Figure 36. Germany Veterinary Biologics Market Share (%), By Disease Type, 2018-2032F
  • Figure 37. Germany Veterinary Biologics Market Share (%), By Application, 2018-2032F
  • Figure 38. Germany Veterinary Biologics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 39. France Veterinary Biologics Market, By Value, In USD Billion, 2018-2032F
  • Figure 40. France Veterinary Biologics Market Share (%), By Product, 2018-2032F
  • Figure 41. France Veterinary Biologics Market Share (%), By Disease Type, 2018-2032F
  • Figure 42. France Veterinary Biologics Market Share (%), By Application, 2018-2032F
  • Figure 43. France Veterinary Biologics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 44. Italy Veterinary Biologics Market, By Value, In USD Billion, 2018-2032F
  • Figure 45. Italy Veterinary Biologics Market Share (%), By Product, 2018-2032F
  • Figure 46. Italy Veterinary Biologics Market Share (%), By Disease Type, 2018-2032F
  • Figure 47. Italy Veterinary Biologics Market Share (%), By Application, 2018-2032F
  • Figure 48. Italy Veterinary Biologics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 49. United Kingdom Veterinary Biologics Market, By Value, In USD Billion, 2018-2032F
  • Figure 50. United Kingdom Veterinary Biologics Market Share (%), By Product, 2018-2032F
  • Figure 51. United Kingdom Veterinary Biologics Market Share (%), By Disease Type, 2018-2032F
  • Figure 52. United Kingdom Veterinary Biologics Market Share (%), By Application, 2018-2032F
  • Figure 53. United Kingdom Veterinary Biologics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 54. Russia Veterinary Biologics Market, By Value, In USD Billion, 2018-2032F
  • Figure 55. Russia Veterinary Biologics Market Share (%), By Product, 2018-2032F
  • Figure 56. Russia Veterinary Biologics Market Share (%), By Disease Type, 2018-2032F
  • Figure 57. Russia Veterinary Biologics Market Share (%), By Application, 2018-2032F
  • Figure 58. Russia Veterinary Biologics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 59. Netherlands Veterinary Biologics Market, By Value, In USD Billion, 2018-2032F
  • Figure 60. Netherlands Veterinary Biologics Market Share (%), By Product, 2018-2032F
  • Figure 61. Netherlands Veterinary Biologics Market Share (%), By Disease Type, 2018-2032F
  • Figure 62. Netherlands Veterinary Biologics Market Share (%), By Application, 2018-2032F
  • Figure 63. Netherlands Veterinary Biologics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 64. Spain Veterinary Biologics Market, By Value, In USD Billion, 2018-2032F
  • Figure 65. Spain Veterinary Biologics Market Share (%), By Product, 2018-2032F
  • Figure 66. Spain Veterinary Biologics Market Share (%), By Disease Type, 2018-2032F
  • Figure 67. Spain Veterinary Biologics Market Share (%), By Application, 2018-2032F
  • Figure 68. Spain Veterinary Biologics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 69. Turkey Veterinary Biologics Market, By Value, In USD Billion, 2018-2032F
  • Figure 70. Turkey Veterinary Biologics Market Share (%), By Product, 2018-2032F
  • Figure 71. Turkey Veterinary Biologics Market Share (%), By Disease Type, 2018-2032F
  • Figure 72. Turkey Veterinary Biologics Market Share (%), By Application, 2018-2032F
  • Figure 73. Turkey Veterinary Biologics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 74. Poland Veterinary Biologics Market, By Value, In USD Billion, 2018-2032F
  • Figure 75. Poland Veterinary Biologics Market Share (%), By Product, 2018-2032F
  • Figure 76. Poland Veterinary Biologics Market Share (%), By Disease Type, 2018-2032F
  • Figure 77. Poland Veterinary Biologics Market Share (%), By Application, 2018-2032F
  • Figure 78. Poland Veterinary Biologics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 79. South America Veterinary Biologics Market, By Value, In USD Billion, 2018-2032F
  • Figure 80. South America Veterinary Biologics Market Share (%), By Product, 2018-2032F
  • Figure 81. South America Veterinary Biologics Market Share (%), By Disease Type, 2018-2032F
  • Figure 82. South America Veterinary Biologics Market Share (%), By Application, 2018-2032F
  • Figure 83. South America Veterinary Biologics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 84. South America Veterinary Biologics Market Share (%), By Country, 2018-2032F
  • Figure 85. Brazil Veterinary Biologics Market, By Value, In USD Billion, 2018-2032F
  • Figure 86. Brazil Veterinary Biologics Market Share (%), By Product, 2018-2032F
  • Figure 87. Brazil Veterinary Biologics Market Share (%), By Disease Type, 2018-2032F
  • Figure 88. Brazil Veterinary Biologics Market Share (%), By Application, 2018-2032F
  • Figure 89. Brazil Veterinary Biologics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 90. Argentina Veterinary Biologics Market, By Value, In USD Billion, 2018-2032F
  • Figure 91. Argentina Veterinary Biologics Market Share (%), By Product, 2018-2032F
  • Figure 92. Argentina Veterinary Biologics Market Share (%), By Disease Type, 2018-2032F
  • Figure 93. Argentina Veterinary Biologics Market Share (%), By Application, 2018-2032F
  • Figure 94. Argentina Veterinary Biologics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 95. Asia-Pacific Veterinary Biologics Market, By Value, In USD Billion, 2018-2032F
  • Figure 96. Asia-Pacific Veterinary Biologics Market Share (%), By Product, 2018-2032F
  • Figure 97. Asia-Pacific Veterinary Biologics Market Share (%), By Disease Type, 2018-2032F
  • Figure 98. Asia-Pacific Veterinary Biologics Market Share (%), By Application, 2018-2032F
  • Figure 99. Asia-Pacific Veterinary Biologics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 100. Asia-Pacific Veterinary Biologics Market Share (%), By Country, 2018-2032F
  • Figure 101. India Veterinary Biologics Market, By Value, In USD Billion, 2018-2032F
  • Figure 102. India Veterinary Biologics Market Share (%), By Product, 2018-2032F
  • Figure 103. India Veterinary Biologics Market Share (%), By Disease Type, 2018-2032F
  • Figure 104. India Veterinary Biologics Market Share (%), By Application, 2018-2032F
  • Figure 105. India Veterinary Biologics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 106. China Veterinary Biologics Market, By Value, In USD Billion, 2018-2032F
  • Figure 107. China Veterinary Biologics Market Share (%), By Product, 2018-2032F
  • Figure 108. China Veterinary Biologics Market Share (%), By Disease Type, 2018-2032F
  • Figure 109. China Veterinary Biologics Market Share (%), By Application, 2018-2032F
  • Figure 110. China Veterinary Biologics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 111. Japan Veterinary Biologics Market, By Value, In USD Billion, 2018-2032F
  • Figure 112. Japan Veterinary Biologics Market Share (%), By Product, 2018-2032F
  • Figure 113. Japan Veterinary Biologics Market Share (%), By Disease Type, 2018-2032F
  • Figure 114. Japan Veterinary Biologics Market Share (%), By Application, 2018-2032F
  • Figure 115. Japan Veterinary Biologics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 116. Australia Veterinary Biologics Market, By Value, In USD Billion, 2018-2032F
  • Figure 117. Australia Veterinary Biologics Market Share (%), By Product, 2018-2032F
  • Figure 118. Australia Veterinary Biologics Market Share (%), By Disease Type, 2018-2032F
  • Figure 119. Australia Veterinary Biologics Market Share (%), By Application, 2018-2032F
  • Figure 120. Australia Veterinary Biologics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 121. Vietnam Veterinary Biologics Market, By Value, In USD Billion, 2018-2032F
  • Figure 122. Vietnam Veterinary Biologics Market Share (%), By Product, 2018-2032F
  • Figure 123. Vietnam Veterinary Biologics Market Share (%), By Disease Type, 2018-2032F
  • Figure 124. Vietnam Veterinary Biologics Market Share (%), By Application, 2018-2032F
  • Figure 125. Vietnam Veterinary Biologics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 126. South Korea Veterinary Biologics Market, By Value, In USD Billion, 2018-2032F
  • Figure 127. South Korea Veterinary Biologics Market Share (%), By Product, 2018-2032F
  • Figure 128. South Korea Veterinary Biologics Market Share (%), By Disease Type, 2018-2032F
  • Figure 129. South Korea Veterinary Biologics Market Share (%), By Application, 2018-2032F
  • Figure 130. South Korea Veterinary Biologics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 131. Indonesia Veterinary Biologics Market, By Value, In USD Billion, 2018-2032F
  • Figure 132. Indonesia Veterinary Biologics Market Share (%), By Product, 2018-2032F
  • Figure 133. Indonesia Veterinary Biologics Market Share (%), By Disease Type, 2018-2032F
  • Figure 134. Indonesia Veterinary Biologics Market Share (%), By Application, 2018-2032F
  • Figure 135. Indonesia Veterinary Biologics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 136. Philippines Veterinary Biologics Market, By Value, In USD Billion, 2018-2032F
  • Figure 137. Philippines Veterinary Biologics Market Share (%), By Product, 2018-2032F
  • Figure 138. Philippines Veterinary Biologics Market Share (%), By Disease Type, 2018-2032F
  • Figure 139. Philippines Veterinary Biologics Market Share (%), By Application, 2018-2032F
  • Figure 140. Philippines Veterinary Biologics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 141. Middle East & Africa Veterinary Biologics Market, By Value, In USD Billion, 2018-2032F
  • Figure 142. Middle East & Africa Veterinary Biologics Market Share (%), By Product, 2018-2032F
  • Figure 143. Middle East & Africa Veterinary Biologics Market Share (%), By Disease Type, 2018-2032F
  • Figure 144. Middle East & Africa Veterinary Biologics Market Share (%), By Application, 2018-2032F
  • Figure 145. Middle East & Africa Veterinary Biologics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 146. Middle East & Africa Veterinary Biologics Market Share (%), By Country, 2018-2032F
  • Figure 147. Saudi Arabia Veterinary Biologics Market, By Value, In USD Billion, 2018-2032F
  • Figure 148. Saudi Arabia Veterinary Biologics Market Share (%), By Product, 2018-2032F
  • Figure 149. Saudi Arabia Veterinary Biologics Market Share (%), By Disease Type, 2018-2032F
  • Figure 150. Saudi Arabia Veterinary Biologics Market Share (%), By Application, 2018-2032F
  • Figure 151. Saudi Arabia Veterinary Biologics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 152. UAE Veterinary Biologics Market, By Value, In USD Billion, 2018-2032F
  • Figure 153. UAE Veterinary Biologics Market Share (%), By Product, 2018-2032F
  • Figure 154. UAE Veterinary Biologics Market Share (%), By Disease Type, 2018-2032F
  • Figure 155. UAE Veterinary Biologics Market Share (%), By Application, 2018-2032F
  • Figure 156. UAE Veterinary Biologics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 157. South Africa Veterinary Biologics Market, By Value, In USD Billion, 2018-2032F
  • Figure 158. South Africa Veterinary Biologics Market Share (%), By Product, 2018-2032F
  • Figure 159. South Africa Veterinary Biologics Market Share (%), By Disease Type, 2018-2032F
  • Figure 160. South Africa Veterinary Biologics Market Share (%), By Application, 2018-2032F
  • Figure 161. South Africa Veterinary Biologics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 162. By Product Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 163. By Disease Type Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 164. By Application Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 165. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 166. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2024